Risk Factor Modification in Patients with Peptic Ulcer Disease

  • Ioana Baiu
  • Dan E. AzaguryEmail author


Peptic ulcer disease (PUD) results from a defect in the gastric or duodenal mucosa and submucosa caused by an imbalance between injurious factors and defense mechanisms in the gastrointestinal (GI) tract. Typically, the most common etiology is an infection with Helicobacter pylori bacterium. Gastrinoma, inflammatory diseases, or medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) can also lead to gastritis and PUD. Environmental factors have also been implicated, but are less well elucidated. Prevention through avoidance of injurious factors is critical. Once PUD has occurred, treatments are targeted toward protecting the gastrointestinal tract with acid suppression and, avoiding further insults, while allowing for time to restore the integrity of the mucosa. If H. pylori infection is confirmed, then multi-antibiotic drug regimens are necessary for treatment of the resultant PUD.


H. pylori Peptic ulcer disease Gastric ulcer Duodenal ulcer Gastritis Zollinger-Ellison syndrome Gastrin Proton pump inhibitors 


  1. 1.
    Lin KJ, García Rodríguez LA, Hernández-Díaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf. 2011;20(7):718–28.CrossRefGoogle Scholar
  2. 2.
    Sonnenberg A. The burden of digestive diseases in the United States. Chapter 15: Peptic ulcer disease. In: Everhart JE, editor. US Dep Health Hum Serv Public Health Serv Natl Inst Health Natl Inst Diabetes Dig Kidney Dis Wash DC US Gov Print Off 2008 NIH Publ. 1994;09(6443):257–408.Google Scholar
  3. 3.
    Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997;92(4):614.PubMedGoogle Scholar
  4. 4.
    Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.CrossRefGoogle Scholar
  5. 5.
    Brown L. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97.CrossRefGoogle Scholar
  6. 6.
    Chong J, Marshall BJ, Barkin JS, McCallum RW, Reiner DK, Hoffman SR, O’Phelan C. Occupational exposure to Helicobacter pylori for the endoscopy professional: a sera epidemiological study. Am J Gastroenterol. 1994;89(11):1987–92.PubMedGoogle Scholar
  7. 7.
    Backert S, Neddermann M, Maubach G, Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2016;21(1):19–25.CrossRefGoogle Scholar
  8. 8.
    Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med. 2004;350:213–5.CrossRefGoogle Scholar
  9. 9.
    Ferreira AC, Isomoto H, Moriyama M, Fujioka T, Machado JC, Yamaoka Y. Helicobacter and gastric malignancies. Helicobacter. 2008;13(1):28–34.CrossRefGoogle Scholar
  10. 10.
    Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol. 2014;20(36):12753–66.CrossRefGoogle Scholar
  11. 11.
    Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808.CrossRefGoogle Scholar
  12. 12.
    Graham DY, Qureshi WA. Markers of infection. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: physiology and genetics. Washington, D.C: ASM Press; 2001. p. 499–510.CrossRefGoogle Scholar
  13. 13.
    Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772–81.CrossRefGoogle Scholar
  14. 14.
    Feldman M, Cryer B, Lee E, Peterson WL. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA. 1998;280(4):363.CrossRefGoogle Scholar
  15. 15.
    Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med. 1995;46:395.CrossRefGoogle Scholar
  16. 16.
    Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295.CrossRefGoogle Scholar
  17. 17.
    Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.CrossRefGoogle Scholar
  18. 18.
    Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther. 2001;15:1555–61.CrossRefGoogle Scholar
  19. 19.
    Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10(2):199–202.CrossRefGoogle Scholar
  20. 20.
    Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Sci. 1995;40:1345–50.CrossRefGoogle Scholar
  21. 21.
    Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594.CrossRefGoogle Scholar
  22. 22.
    Wallace JL. How do NSAIDs cause ulcer disease? Baillieres Best Pr Res Clin Gastroenterol. 2000;14(1):147–59.CrossRefGoogle Scholar
  23. 23.
    Tseng CL, Chen YT, Huang CJ, Luo JC, Peng YL, Huang DF, Hou MC, Lin HC, Lee FY. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. Aliment Pharmacol Ther. 2015 Sep;42(5):599–606.CrossRefGoogle Scholar
  24. 24.
    Maity P, Biswas K, Roy S, Banerjee RK, Bandyopadhyay U. Smoking and the pathogenesis of gastroduodenal ulcer – recent mechanistic update. Mol Cell Biochem. 2003;253(1–2):329–38.CrossRefGoogle Scholar
  25. 25.
    Feldman RA. Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In: Helicobacter Pylori Mol Cell Biol. Wymondham: Horizon Scientific Press; 2001. p. 29–51.Google Scholar
  26. 26.
    Laine L, Hopkins R, Girardi L. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 1998 Sep;93(9):1409–15.PubMedGoogle Scholar
  27. 27.
    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–38.CrossRefGoogle Scholar
  28. 28.
    Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection – a meta-analysis. Aliment Pharmacol Ther. 1999;13:857–64.CrossRefGoogle Scholar
  29. 29.
    MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–74.CrossRefGoogle Scholar
  30. 30.
    Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329(7472):948.CrossRefGoogle Scholar

Copyright information

© SAGES 2019

Authors and Affiliations

  1. 1.Department of SurgeryStanford Health CareStanfordUSA
  2. 2.Bariatric & Minimally Invasive Surgery, Department of SurgeryStanford University School of MedicineStanfordUSA

Personalised recommendations